Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 8/20 | 0.56 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.56 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028796 | 0.93 | BCHE (0.58) | BCHEEPHX2DRD4SLC6A12SLC6A13 | |
| SCHEMBL5364553 | 0.86 | DRD4 (0.65) | BCHEEPHX2DRD4KMT2ACYP1A2 | |
| SCHEMBL13538758 | 0.86 | DRD4 (0.57) | EPHX2DRD4CYP1A2CYP2D6CCR3 | |
| SCHEMBL2424663 | 0.85 | RAB9A (0.65) | BCHEEPHX2DRD4RAB9ACCR3 | |
| SCHEMBL7368209 | 0.85 | SLC6A12 (0.60) | EPHX2DRD4SLC6A12SLC6A13NPC1 | |
| SCHEMBL3026490 | 0.83 | HDAC4 (0.60) | EPHX2DRD4CYP1A2CYP2D6CCR3 | |
| SCHEMBL2462808 | 0.83 | EPHX2 (0.60) | BCHEEPHX2DRD4NPC1RAB9A | |
| SCHEMBL2769124 | 0.82 | DRD4 (0.61) | EPHX2DRD4CYP1A2CYP2D6CCR3 | |
| SCHEMBL2770194 | 0.82 | DRD4 (0.61) | EPHX2DRD4CYP1A2CYP2D6CCR3 | |
| SCHEMBL5429645 | 0.82 | DRD4 (0.61) | EPHX2DRD4CYP1A2CYP2D6CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501737-B2 | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-06 | — | — | US | disclosed |
| US-8501737-B2 | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-06 | — | — | US | disclosed |
| US-20100009988-A1 | PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN | 2010-01-14 | — | — | US | disclosed |
| US-20100009988-A1 | PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN | 2010-01-14 | — | — | US | disclosed |
| US-7592450-B2 | used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-22 | — | — | US | disclosed |
| US-7592450-B2 | used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-22 | — | — | US | disclosed |
| WO-2003076438-A1 | PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009988-A1 | PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC5 | BCHE 2731/4885EPHX2 3749/4885DRD4 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.